Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DGP6V3
|
|||
| Drug Name |
BAP-15
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Preclinical | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Isopeptidase T (USP5) | Target Info | Inhibitor | [2] |
| Ubiquitin carboxyl-terminal hydrolase 14 (USP14) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014 Jan;124(1):6-12. | |||
| REF 2 | The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.